ClinicalTrials.gov record
Completed Phase 2 Interventional

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

ClinicalTrials.gov ID: NCT05005728

Public ClinicalTrials.gov record NCT05005728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer

Study identification

NCT ID
NCT05005728
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Xencor, Inc.
Industry
Enrollment
72 participants

Conditions and interventions

Interventions

  • vudalimab + cabazitaxel or docetaxel Combination Product
  • vudalimab + carboplatin + cabazitaxel Combination Product
  • vudalimab + docetaxel Combination Product
  • vudalimab + olaparib Combination Product
  • vudalimab monotherapy Biological

Combination Product · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 21, 2021
Primary completion
Jun 9, 2025
Completion
Jun 9, 2025
Last update posted
May 4, 2026

2021 – 2025

United States locations

U.S. sites
26
U.S. states
20
U.S. cities
26
Facility City State ZIP Site status
Alaska Oncology and Hematology Anchorage Alaska 99508
Palo Verde Hematology Oncology Glendale Arizona 85304
Mayo Clinic Hospital Phoenix Arizona 85054
City of Hope Duarte California 91010
VA Greater Los Angeles Los Angeles California 90064
University of California, San Diego San Diego California 92093
Rocky Mountain Cancer Centers Lone Tree Colorado 80124
Mayo Clinic Jacksonville Florida 32224
The University of Chicago Medical Center Chicago Illinois 60637
University of Iowa Hospitals & Clinics Iowa City Iowa 52242
University of Kansas Clinical Research Center Fairway Kansas 66205
Mayo Clinic Rochester Minnesota 55905
GU Research Network/Urology Cancer Center Omaha Nebraska 68130
Comprehensive Cancer Centers of Nevada Las Vegas Nevada 89148
XCancer New Mexico Oncology Hematology Consultants, Ltd. Albuquerque New Mexico 87109
Columbia University New York New York 10032
Montefiore Medical Center The Bronx New York 10461
Northwest Cancer Specialists Tigard Oregon 97223
University of Pennsylvania Philadelphia Pennsylvania 19104
UPMC Hillman Cancer Center Pittsburgh Pennsylvania 15232
Carolina Urologic Research Center Myrtle Beach South Carolina 29572
SCRI Oncology Partners Nashville Tennessee 37203
Texas Oncology-Central South Weslaco Texas 78596
Virginia Cancer Specialists Fairfax Virginia 22031
Virginia Oncology Associates Norfolk Virginia 23502
University of Washington/Seattle Cancer Care/Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05005728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05005728 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →